Conclusions: Our findings suggest that CQ interferes with the PICALM/AP2/clathrin machinery which controls NIS endocytosis, identifying it as an FDA-approved pharmaceutical agent which alters NIS endocytosis, with translatable potential to improve radioiodide therapy in thyroid cancer. Here, SLC5A5 is linked to thyroid gland carcinoma.